TYKERB Drug Patent Profile

Which patents cover Tykerb, and what generic alternatives are available?

Tykerb is a drug marketed by Novartis and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty-eight patent family members in twenty-six countries.

The generic ingredient in TYKERB is lapatinib ditosylate. There are seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the lapatinib ditosylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tykerb

A generic version of TYKERB was approved as lapatinib ditosylate by NATCO PHARMA LTD on September 29^th, 2020.

Summary for TYKERB

International Patents:	28
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	101
Clinical Trials:	96
Patent Applications:	4,789
Drug Prices:	Drug price information for TYKERB
What excipients (inactive ingredients) are in TYKERB?	TYKERB excipients list
DailyMed Link:	TYKERB at DailyMed

See drug prices for TYKERB

Recent Clinical Trials for TYKERB

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Aslan Pharmaceuticals	Phase 2
Scariot Foundation	N/A
GlaxoSmithKline	N/A

See all TYKERB clinical trials

Pharmacology for TYKERB

Drug Class	Kinase Inhibitor
Mechanism of Action	Protein Kinase Inhibitors

Paragraph IV (Patent) Challenges for TYKERB

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TYKERB	Tablets	lapatinib ditosylate	250 mg	022059	1	2011-03-14

US Patents and Regulatory Information for TYKERB

TYKERB is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	TYKERB	lapatinib ditosylate	TABLET;ORAL	022059-001	Mar 13, 2007	AB	RX	Yes	Yes			Y	Y

Expired US Patents for TYKERB

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	TYKERB	lapatinib ditosylate	TABLET;ORAL	022059-001	Mar 13, 2007
Novartis	TYKERB	lapatinib ditosylate	TABLET;ORAL	022059-001	Mar 13, 2007
Novartis	TYKERB	lapatinib ditosylate	TABLET;ORAL	022059-001	Mar 13, 2007
Novartis	TYKERB	lapatinib ditosylate	TABLET;ORAL	022059-001	Mar 13, 2007
Novartis	TYKERB	lapatinib ditosylate	TABLET;ORAL	022059-001	Mar 13, 2007
Novartis	TYKERB	lapatinib ditosylate	TABLET;ORAL	022059-001	Mar 13, 2007

International Patents for TYKERB

When does loss-of-exclusivity occur for TYKERB?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Canada

European Patent Office

Mexico

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TYKERB around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	054252	COMPOSICION FARMACEUTICA ORAL QUE CONTIENE SALES DE DITOSILATO DE 4-QUINAZOLINAMINA
South Korea	20070100936
Argentina	066982	COMPUESTOS HETEROAROMATICOS SUSTITUIDOS COMO INHIBIDORESS TIROSIN QUINASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENE Y SU USO EN LA PREPARACION DE MEDICAMENTOS
Slovenia	1047694
Portugal	1047694
Slovakia	10502000	BICYKLICKÉ HETEROAROMATICKÉ ZLÚČENINY, SPÔSOB ICH PRÍPRAVY, FARMACEUTICKÝ PROSTRIEDOK S ICH OBSAHOM A ICH POUŽITIE (BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASEì (54) INHIBITORS)
Denmark	1454907

Supplementary Protection Certificates for TYKERB

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1047694	SPC/GB08/044	United Kingdom		PRODUCT NAME: LAPATINIB OR A SALT OR SOLVATE THEREOF; REGISTERED: UK EU/1/07/440/001 20080610; UK EU/1/07/440/002 20080610
1047694	91475	Luxembourg		91475, EXPIRES: 20230610
1047694	122008000048	Germany		PRODUCT NAME: LAPATINIB ODER EIN SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/07/440/001-002 20080610
1047694	331	Finland
1047694	37/2008	Austria		PRODUCT NAME: LAPATINIB ALS FREIE BASE ODER EIN SALZ ODER EIN SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/07/440/001-002 20080610
1047694	300360	Netherlands		DETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), OVERDRACHT
1047694	SZ 37/2008	Austria		PRODUCT NAME: LAPATINIB ALS FREIE BASE ODER EIN SALZ ODER EIN SOLVAT DAVON

Market Dynamics and Financial Trajectory for Tykerb (Lapatinib)

Last updated: February 19, 2026

What is the current market status of Tykerb (Lapatinib)?

Tykerb (lapatinib) is an oral tyrosine kinase inhibitor targeting HER2-positive and hormone receptor-positive breast cancer. Produced by GlaxoSmithKline (GSK), it was approved by the FDA in 2007 for metastatic breast cancer. As of 2023, the drug maintains a niche position within breast cancer treatment, facing increasing competition from novel therapies.

What are the sales and revenue trends for Tykerb?

• Global sales revenue in 2022: Approximately $80 million.
• Peak sales period: 2012-2014, with revenues reaching $200 million annually.
• Recent trend: Declining sales attributed to treatment paradigm shifts and patent expiration.

Year	Estimated Revenue (USD millions)	Notes
2018	120	Off-label use declined, patent nearing expiry
2020	95	Market share reduced by new competitors
2022	80	Continued decline

Sources: IQVIA, GSK annual reports, industry reports.

How has patent expiration impacted market exclusivity?

• Patent expiration date: 2018, in key markets like the U.S. and Europe.
• Generic entry: Multiple biosimilars and generics entered the market post-2018.
• Impact: Reduced price premiums and sales volume; price erosion reported up to 50% based on market post-patent expiry.

What competitive forces influence the market?

Main competitors

• Kadcyla (trastuzumab emtansine): Approved for similar indications with proven efficacy.
• Perjeta (pertuzumab): Often combined with trastuzumab and chemotherapy.
• Kytril (lapatinib + capecitabine): Combination therapy gains favor due to improved outcomes.

Emerging treatment options

• Novel HER2-targeted agents: Neratinib (Nerlynx), tucatinib (Tukysa), show improved progression-free survival.
• Antibody-drug conjugates: Enhertu, Trastuzumab deruxtecan, are shifting treatment standards.
• CDK4/6 inhibitors: Combined with endocrine therapy for hormone receptor-positive disease.

Pricing and reimbursement

• Generics and biosimilars have reduced patient and payor costs, limiting revenue potential.
• Reimbursement policies favor newer agents with higher efficacy profiles.

What is the future financial outlook?

Projected sales trajectory

• Sales are expected to decline further over the next five years, potentially reaching below $50 million annually after 2025.
• Market share will shrink as competitors expand indications and improve efficacy.

Strategic considerations for GSK

• Pipeline development: Incorporate lapatinib into combination regimens or expand into new indications.
• Partnerships: License agreements with biotech firms developing next-generation HER2 inhibitors.
• Pricing strategy: Adjust to competitive pressures, focusing on niche or combination therapies.

Regulatory environment

• Patent challenges and biosimilar approvals likely to intensify globally.
• Accelerated approval pathways may enable faster market entry for competitors.

How do regulatory decisions impact the drug’s financial trajectory?

• Approvals of new competitors or biosimilars have depressed pricing.
• Re-approvals or supplemental indications could stabilize revenues.
• Any regulatory hurdles for combination therapy approvals may restrict growth opportunities.

What are the key risks and opportunities?

Risks	Opportunities
Market share erosion	Collaborate on combination therapies
Patent expiration	Expand indications through clinical trials
Competition from novel agents	Develop next-generation HER2 inhibitors

Summary

Tykerb (lapatinib) retains limited market share post-patent expiry, with revenues declining steadily. Industry trends favor newer agents and antibody-drug conjugates, suppressing sales growth. GSK’s strategic focus might transition toward pipeline expansion and niche market positions. Financial stability relies on innovation, strategic alliances, and navigating competitive and regulatory environments.

Key Takeaways

• Tykerb's peak sales occurred before patent expiration, with revenues declining since 2018.
• Biosimilar and generic competition significantly weigh on pricing and sales.
• The rise of newer, more effective HER2-targeted therapies diminishes the drug's market share.
• Future revenues depend on pipeline development and strategic positioning amid evolving standards of care.
• Regulatory rulings and patent landscapes continue to influence the drug’s financial outlook.

FAQs

1. Will Tykerb regain market share with new indications?
   Unlikely, as competition and emerging therapies dominate. Limited expansion beyond current approved uses restricts upside.

2. Are biosimilars a threat to Tykerb’s profitability?
   Biosimilars' entry has driven down prices, reducing revenue margins and sales volume.

3. What is the outlook for Tykerb's patents?
   Patents expired in 2018 in key markets; further patent protections are unlikely.

4. Can combination therapies revive Tykerb sales?
   Potentially, if clinical trials demonstrate superior outcomes, but competition from newer agents reduces feasibility.

5. How does the pipeline affect Tykerb's future?
   Development of next-generation inhibitors could either overshadow Tykerb or provide renewal if combined effectively.

---

References

[1] IQVIA. (2023). Pharmaceutical sales data.
[2] GSK. (2022). Annual report.
[3] FDA. (2007). Lapatinib approval letter.
[4] Evaluate Pharma. (2022). Market forecasts for HER2-positive breast cancer therapies.
[5] European Medicines Agency. (2018). Patent expiry and biosimilar entries.